Mecamylamine - Vyera Pharmaceuticals

Drug Profile

Mecamylamine - Vyera Pharmaceuticals

Alternative Names: Mecamine-hydrochloride; Mecamylamine-hydrochloride; Vecamyl

Latest Information Update: 12 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Retrophin
  • Developer Vyera Pharmaceuticals
  • Class Eye disorder therapies; Norbornanes; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Nicotinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Autistic disorder

Most Recent Events

  • 01 Sep 2017 Turing Pharmaceuticals is now called Vyera Pharmaceuticals (Vyera Pharmaceuticals California Comprehensive Compliance Program, September 2017)
  • 24 Feb 2015 Turing Pharmaceuticals acquires Vecamyl® from Retrophin
  • 24 Feb 2015 Early research in Autistic disorder in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top